Trial Profile
A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Nivolumab (Primary) ; Prednisolone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms HO152; HOVON 152 DLBCL
- 23 Jan 2024 Planned primary completion date changed from 1 Oct 2023 to 1 Jan 2024.
- 12 Dec 2023 Results assessing the efficacy and safety profile of the induction phase with DA-EPOCH-R, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 06 Jan 2023 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2023.